These modifications are central to good health and require specific motivational and cognitive intervention strategies designed to promote adherence to these healthy behaviors. High-quality evidence supporting some of these strategies is provided in Online Data Supplement G. Additionally, interventions such as goal setting, provision of feedback, self-monitoring, follow-up, motivational interviewing, and promotion of self-sufficiency are most effective when com- bined. Most individuals have clear expectations about what a new lifestyle will provide; if their experiences do not match these expectations, they will be dissatisfied and less moti- vated to maintain a lifestyle change, particularly in envi- ronments that do not support healthy choices. Other factors that may influence adoption and maintenance of new physi- cal activity or dietary behaviors include age, sex, baseline health status, and body mass index, as well as the presence of comorbid conditions and depression, which negatively affect adherence to most lifestyle change regimens.S12.1.2-1 Primary strategies include cognitive-behavioral strategies for pro- moting behavior change, intervention processes and delivery strategies, and addressing cultural and social context vari- ables that influence behavioral change. Recommendation-Specific Supportive Text 1. It is crucial to translate and implement into practice the most effective evidence-based strategies for ad- herence to nonpharmacological treatment for hyper- tension. Both adoption and maintenance of new CVD risk-reducing behaviors pose challenges for many in- dividuals. Success requires consideration of race, eth- nicity, and socioeconomic status, as well as individual, provider, and environmental factors that may influence the design of such interventions.S12.1.2-1 High-quality evi- dence has shown that even modest sustained lifestyle changes can substantially reduce CVD morbidity and Because many beneficial effects of lifestyle changes accrue over time, long-term adher- ence maximizes individual and population benefits.


Success requires consideration of race, eth- nicity, and socioeconomic status, as well as individual, provider, and environmental factors that may influence the design of such interventions.S12.1.2-1 High-quality evi- dence has shown that even modest sustained lifestyle changes can substantially reduce CVD morbidity and Because many beneficial effects of lifestyle changes accrue over time, long-term adher- ence maximizes individual and population benefits. Interventions targeting sodium restriction, other dietary patterns, weight reduction, and new physical activity habits often result in impressive rates of initial behavior changes but frequently are not translated into long-term behavioral maintenance. 12.1.3. Improving Quality of Care for Resource-Constrained Populations The availability of financial, informational, and instrumental support resources can be important though not sole determi- nants of hypertension control.S12.1.3-1,S12.1.3-2 The management of hypertension in resource-constrained populations poses a challenge that will require the implementation of all recom- mendations discussed in Section 13 (Table 21), with specific sensitivity to challenges posed by limited financial resources, including those related to health literacy, alignment of and potential need to realign healthcare priorities by patients, the convenience and complexity of the management strategy, accessibility to health care, and health-related costs (includ- ing medications). Resource-constrained populations are also populations with high representation of groups most likely to manifest health disparities, including racial and ethnic minorities (see Section 10.1), residents located in rural areas, and older adults. The more comprehensive BP targets pro- posed in the present guideline will present added challenges in these populations. It is crucial to invest in measures to enhance health lit- eracy and reinforce the importance of adhering to treatment strategies, while paying attention to cultural sensitivities. These measures may include identification of and partner- ing with community resources and organizations devoted to hypertension control and cardiovascular health.


These measures may include identification of and partner- ing with community resources and organizations devoted to hypertension control and cardiovascular health. Although comparative-effectiveness data documenting efficacy of various interventions are limited, multidisciplinary team based approaches and the use of community health work- ers (see Sections 12.1.1 and 12.2) have shown some utility, as has the use of out-of-office BP monitoring (or no-cost BP control visits), particularly among resource-constrained Long-acting once-daily medica- tions (eg, chlorthalidone, amlodipine) that are now avail- able generically and often on discount formularies can often be used to reduce complexity of the regimen and promote adherence by decreasing the effect of missed medication dosages. When possible, prescriptions requiring longer than 30-day refills should be considered, especially once a Table 21. Clinician s Sequential Flow Chart for the Management of Hypertension Clinician s Sequential Flow Chart for the Management of Hypertension Measure office BP accurately Section 4 Detect white coat hypertension or masked hypertension by using ABPM and HBPM Evaluate for secondary hypertension Section 5 Identify target organ damage Sections 5 and 7 Introduce lifestyle interventions Section 6 Identify and discuss treatment goals Sections 7 and 8 Use ASCVD risk estimation to guide BP threshold for drug therapy Align treatment options with comorbidities Section 9 Account for age, race, ethnicity, sex, and special circumstances in antihypertensive treatment Initiate antihypertensive pharmacological therapy Insure appropriate follow-up Section 8 Use team-based care Section 12 Connect patient to clinician via telehealth Section 12 Detect and reverse nonadherence Section 12 Detect white coat effect or masked uncontrolled hypertension Use health information technology for remote monitoring and self-monitoring of BP ABPM indicates ambulatory blood pressure monitoring; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; and HBPM, home blood pressure monitoring. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e73 stable regimen is achieved.


Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e73 stable regimen is achieved. Where appropriate, using scored tablets and pill cutters can decrease the cost of medication for patients. 12.2. Structured, Team-Based Care Interventions for Hypertension Control Recommendation for Structured, Team-Based Care Interventions for Hypertension Control References that support the recommendation are summarized in Online Data Supplement 62. COR LOE Recommendation I A 1. A team-based care approach is recommended for adults with Synopsis Team-based care to improve BP control is a health sys- tems level, organizational intervention that incorporates a multidisciplinary team to improve the quality of hyperten- sion care for patients.S12.2-8 S12.2-10 Various team-based hyper- tension care models have been demonstrated to increase the proportion of individuals with controlled BP and to reduce both SBP and DBP.S12.2-1 S12.2-7,S12.2-11,S12.2-12 A team-based care approach is patient centered and is frequently implemented as part of a multifaceted approach, with systems support for clinical decision making (ie, treatment algorithms), collabo- ration, adherence to prescribed regimen, BP monitoring, and patient self-management. Team-based care for hypertension includes the patient, the patient s primary care provider, and other professionals, such as cardiologists, nurses, pharma- cists, physician assistants, dietitians, social workers, and community health workers. These professionals complement the activities of the primary care provider by providing pro- cess support and sharing the responsibilities of hypertension care. Section 13 contains a comprehensive, patient-centered plan of care that should be the basis of all team-based care for hypertension.


Section 13 contains a comprehensive, patient-centered plan of care that should be the basis of all team-based care for hypertension. Team-based care aims to achieve effective control of hypertension by application of the strategies outlined in Online Data Supplement H.S12.2-3 Delineation of individual team member roles on the basis of knowledge, skill set, and availability, as well as the patient s needs, allows the pri- mary care provider to delegate routine matters to the team, thereby permitting more time to manage complex and criti- cal patient-care issues. Important implementation aspects, such as type of team member added, role of team members related to medication management, and number of team members, influence BP outcomes.S12.2-3,S12.2-13 Team member roles should be clear to all team members and to patients and families. Team-based care often requires organizational change and reallocation of resources.S12.2-14,S12.2-15 Systems-level sup- port, such as use of electronic health records (EHR) (see Section 12.3.1), clinical decision support (ie, treatment algo- rithms), technology-based remote monitoring (see Section 12.3.2), self-management support tools, and monitoring of performance, are likely to augment and intensify team-based care efforts to reduce high BP. Recommendation-Specific Supportive Text 1. RCTs and meta-analyses of RCTs of team-based hyper- tension care involving nurse or pharmacist intervention demonstrated reductions in SBP and DBP and/or greater achievement of BP goals when compared with usual Similarly, systematic reviews of team-based care, including a review of studies that in- cluded community health workers, for patients with pri- mary hypertension showed reductions in SBP and DBP and improvements in BP control, appointment keeping, and hypertension medication adherence as compared with usual care.S12.2-3,S12.2-12 12.3. Health Information Technology Based Strategies to Promote Hypertension Control 12.3.1. EHR and Patient Registries Recommendations for EHR and Patient Registries References that support recommendations are summarized in Online Data Supplement 63.


EHR and Patient Registries Recommendations for EHR and Patient Registries References that support recommendations are summarized in Online Data Supplement 63. COR LOE Recommendations I B-NR 1. Use of the EHR and patient registries is beneficial for identification of patients with undiagnosed or undertreated I B-NR 2. Use of the EHR and patient registries is beneficial for guiding quality improvement efforts designed to improve hypertension control.S12.3.1-1 S12.3.1-3 Synopsis A growing number of health systems are developing or using registries and EHR that permit large-scale queries to sup- port population health management strategies to identify undiagnosed or undertreated hypertension. Such innovations are implemented as ongoing quality improvement initia- tives in clinical practice. To reduce undiagnosed hyperten- sion and improve hypertension management, a multipronged approach may include 1) application of hypertension screen- ing algorithms to EHR databases to identify at-risk patients, 2) contacting at-risk patients to schedule BP measurements, 3) monthly written feedback to clinicians about at-risk patients who have yet to complete a BP measurement, and 4) electronic prompts for BP measurements whenever at-risk patients visit Recommendation-Specific Supportive Text 1. A growing number of health systems have implemented secure EHR and are developing databases that permit large-scale queries to support population health manage- ment strategies for more effective and accurate identifica- tion of patients with hypertension.S12.3.1-1 S12.3.1-3 2. A growing number of health systems have implemented secure EHR and are developing databases that permit large-scale quality improvement initiative designed queries to support population health management strategies for more effective management and control 12.3.2. Telehealth Interventions to Improve Hypertension Control Recommendation for Telehealth Interventions to Improve Hypertension Control References that support the recommendation are summarized in Online Data Supplement 64. COR LOE Recommendation IIa A 1.


Telehealth Interventions to Improve Hypertension Control Recommendation for Telehealth Interventions to Improve Hypertension Control References that support the recommendation are summarized in Online Data Supplement 64. COR LOE Recommendation IIa A 1. Telehealth strategies can be useful adjuncts to interventions shown to reduce BP for adults with Synopsis Telehealth strategies, such as telemedicine, digital health ( eHealth ), and use of mobile computing and communica- tion technologies ( mHealth ), are new and innovative tools to facilitate improvements in managing patients with hyperten- sion. mHealth interventions show promise in reducing SBP in patients with hypertension but with large variability in behav- ioral targets, intervention components, delivery modalities, and patient engagement.S12.3.2-5 In addition, there are important implications for the role of social networks, social media, and electronic technology as viable components of weight man- agement and other lifestyle modification and disease manage- Commonly used telehealth interventions for hyperten- sion management are listed in Online Data Supplement I. Wireless technologies (Online Data Supplement I) allow link- ing BP devices and other measurement devices to telephone- or Internet-based transmission systems or to Wi-Fi access points available in users homes and in communities. Some systems require patients to manually enter data, which is then forwarded to a remote computer or the mobile device of the telehealth provider through a telephone line or the Internet.S12.3.2-7 When data are received, they are stored and analyzed, and reports are generated, including variations and averages in BP and other parameters over the recording period. Recommendation-Specific Supportive Text 1. Meta-analyses of RCTs of different telehealth inter- ventions have demonstrated greater SBP and DBP and a larger proportion of patients achieving BP controlS12.3.2-2 than those achieved with usual care without telehealth.


Meta-analyses of RCTs of different telehealth inter- ventions have demonstrated greater SBP and DBP and a larger proportion of patients achieving BP controlS12.3.2-2 than those achieved with usual care without telehealth. The effect of various telehealth interventions on BP lowering was signifi- cantly greater than that of BP self-monitoring without transmission of BP data, which suggests a possible add- ed value of the teletransmission approach.S12.3.2-1,S12.3.2-3 Although mHealth interventions in general showed promise in reducing SBP in patients with hyperten- sion, results were inconsistent.S12.3.2-5 It is unclear which combination of telehealth intervention features is most effective, and telehealth has not been demonstrated to be effective as a standalone strategy for improving hypertension control. 12.4. Improving Quality of Care for Patients With Hypertension 12.4.1. Performance Measures Recommendation for Performance Measures References that support the recommendation are summarized in Online Data Supplement 65. COR LOE Recommendation IIa B-NR 1. Use of performance measures in combination with other quality improvement strategies at patient-, provider-, and system- based levels is reasonable to facilitate optimal hypertension control.S12.4.1-1 S12.4.1-3 Synopsis Efforts to improve suboptimal medical care include the use of performance measures, which are defined as standardized, vali- dated approaches to assess whether correct healthcare processes are being performed and that desired patient outcomes are being Performance measures are often combined with other quality improvement strategies, such as certification or financial incentives tied to higher-quality care.S12.4.1-5 Guidelines help define clinical care standards that can be used to develop per- formance measures.As guidelines evolve over time to incorporate new evidence, related performance measures may also evolve.


Use of performance measures in combination with other quality improvement strategies at patient-, provider-, and system- based levels is reasonable to facilitate optimal hypertension control.S12.4.1-1 S12.4.1-3 Synopsis Efforts to improve suboptimal medical care include the use of performance measures, which are defined as standardized, vali- dated approaches to assess whether correct healthcare processes are being performed and that desired patient outcomes are being Performance measures are often combined with other quality improvement strategies, such as certification or financial incentives tied to higher-quality care.S12.4.1-5 Guidelines help define clinical care standards that can be used to develop per- formance measures.As guidelines evolve over time to incorporate new evidence, related performance measures may also evolve. Because identification, treatment, and control of hyperten- sion are suboptimal, performance measures for hypertension control have been developed and recommended for use in qual- ity improvement projects aimed at improving hypertension control and related outcomes in clinical practice.S12.4.1-6 S12.4.1-8 Because the specific methods used in performance measures can have an impact on their accuracy and ultimate impact (eg, the method of BP measurement used in the assessment), they should be developed, tested, and implemented according to See Online Data Supplement J for publicly available performance measures to assess the quality of hypertension care (generally using JNC 7 criteria). Recommendation-Specific Supportive Text 1. RCTs on the impact of performance measures on hyper- tension control are lacking; RCTs of quality improve- ment protocols have shown improvements in hypertension Furthermore, a large observational study showed that a systematic approach to hypertension control, including the use of performance measures, was associated with significant improvement in hypertension control compared with historical control groups.S12.4.1-3 12.4.2. Quality Improvement Strategies Recommendation for Quality Improvement Strategies References that support the recommendation are summarized in Online Data Supplements 66 and 67. COR LOE Recommendation IIa B-R 1.


Quality Improvement Strategies Recommendation for Quality Improvement Strategies References that support the recommendation are summarized in Online Data Supplements 66 and 67. COR LOE Recommendation IIa B-R 1. Use of quality improvement strategies at the health system, provider, and patient levels to improve identification and control of hypertension can be effective.S12.4.2-1 S12.4.2-8 Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e75 Synopsis High-quality BP management is multifactorial and requires the engagement of patients, families, providers, and healthcare The difference between patient out- comes achieved with current hypertension treatment methods and patient outcomes thought to be possible with best-practice treatment methods is known as a quality gap, and such gaps are at least partly responsible for the loss of thousands of lives This includes expanding patient and healthcare provider awareness, appropriate lifestyle modifications, access to care, evidence-based treatment, a high level of medication adherence, and adequate follow-up.S12.4.2-9 Quality improvement strategies or interventions aimed at reducing the quality gap for a group of patients who are representative of those encoun- tered in routine practice have been effective in improving the hypertension care and outcomes across a wide variety of clinic and community settings.S12.4.2-1 S12.4.2-4,S12.4.2-6,S12.4.2-8,S12.4.2-10 Hypertension quality improvement strategies, with exam- ples of substrategies that have been demonstrated to reduce BP and improve BP, are provided in Online Data Supplement E. Because the effects of the different quality improvement strategies varied across trials, and most trials included >1 qual- ity improvement strategy, it is not possible to discern which specific quality improvement strategies have the greatest effects. Team-based care (see Section 12.4) and an organized system of regular review, with antihypertensive drug therapy implemented via a stepped-care protocol, had a clinically sig- nificant effect on reducing SBP and DBP and improving BP control.


Team-based care (see Section 12.4) and an organized system of regular review, with antihypertensive drug therapy implemented via a stepped-care protocol, had a clinically sig- nificant effect on reducing SBP and DBP and improving BP control. The assessed strategies in Online Data Supplement E may be beneficial under some circumstances and in varying National initiatives such as Million Hearts Make Control Your Goal Blood Pressure Toolkit and Team Up Pressure Down provide quality improvement tools to support hypertension care in communities and clinical For other national and regional initiatives to improve hypertension, see Online Data Supplement G. Recommendation-Specific Supportive Text 1. Systematic review and meta-analyses of trials of quality improvement interventions at health system, provider, and patient levels have demonstrated greater SBP and DBP re- ductions and a larger proportion of patients achieving BP control than those observed with no intervention or usual care. Multicomponent and multilevel strategies at the lo- cal community and healthcare delivery system levels have been shown to improve BP control.S12.4.2-6,S12.4.2-7 12.5. Financial Incentives Recommendations for Financial Incentives References that support recommendations are summarized in Online Data Supplement 68. COR LOE Recommendations IIa B-R 1. Financial incentives paid to providers can be useful in achieving improvements in treatment and management of patient populations with hypertension.S12.5-1 S12.5-3 IIa B-NR 2. Health system financing strategies (eg, insurance coverage and copayment benefit design) can be useful in facilitating improved medication adherence and BP control in patients with hypertension.S12.5-4 Synopsis With the evolution of the US health system to reward value over volume, payment systems have focused on financial incentives to improve quality of care. Use of performance measures promulgated by national organizations, govern- mental payers, and commercial payers have fostered greater attention to control of high BP among healthcare providers and their patients.


Use of performance measures promulgated by national organizations, govern- mental payers, and commercial payers have fostered greater attention to control of high BP among healthcare providers and their patients. These performance measures have formed the basis for determining financial incentives for pay for performance initiatives, commercial insurer pay-for-value contracts, and the Medicare Shared Savings Programs devel- oped by the Centers for Medicare & Medicaid Services Innovation for Accountable Care Organizations. In addi- tion, the Centers for Medicare and Medicaid Services has developed The Million Hearts: Cardiovascular Disease Risk Reduction Model, which is an RCT designed to iden- tify and test scalable models of care delivery that reduce Greater attention is being paid to the influence of health insurance coverage and benefit designs focused on reducing patient copayments for antihypertensive medications. Recommendation-Specific Supportive Text 1. Moderate-quality evidence with mixed results sug- gests that population-based payment incentive pro- grams can play an important role in achieving better BP 2. Reduced copayments for health care, including for medi- cations, and improved outcomes of hypertension care have been identified in several US studies and in single studies in Finland, Israel, and Brazil.S12.5-4 This is con- sistent with other evidence on how copayments reduce uptake of care and has implications for policy makers, particularly because the balance of evidence does not suggest that reducing medication copayments leads to an increase in overall healthcare expenditure. 13. The Plan of Care for Hypertension Recommendation for the Plan of Care for Hypertension COR LOE Recommendation I C-EO 1. Every adult with hypertension should have a clear, detailed, and current evidence-based plan of care that ensures the achievement of treatment and self-management goals, encourages effective management of comorbid conditions, prompts timely follow- up with the healthcare team, and adheres to CVD GDMT (Table 22).


Every adult with hypertension should have a clear, detailed, and current evidence-based plan of care that ensures the achievement of treatment and self-management goals, encourages effective management of comorbid conditions, prompts timely follow- up with the healthcare team, and adheres to CVD GDMT (Table 22). Recommendations for Financial Incentives (Continued) COR LOE Recommendations Synopsis A specific plan of care for hypertension is essential and should reflect understanding of the modifiable and nonmodifiable determinants of health behaviors, including the social deter- minants of risk and outcomes. A clinician s sequential flow chart for management of hypertension is presented in Table 21. Detailed evidence-based elements of the plan of care are listed in Table 22. The determinants will vary among demographic subgroups (see Section 10 for additional information). Recommendation-Specific Supportive Text 1. Studies demonstrate that implementation of a plan of care for hypertension can lead to sustained reduction of BP and attainment of BP targets over several years.S13-1 S13-6 Meta-analysis of RCTs shows reductions in BP of pa- tients with hypertension and achievement of BP goals at 6 months and 1 year when compared with usual care. 13.1. Health Literacy Communicating alternative behaviors that support self- management of healthy BP in addition to medication adher- ence is important. This should be done both verbally and in writing. Today, mobile phones have a recording option. For patients with mobile phones, the phone can be used to inform patients and family members of medical instructions after the doctor s visit as an additional level of communication. Inclusion of a family member or friend that can help interpret and encourage self-management treatment goals is suggested when appropriate.


Inclusion of a family member or friend that can help interpret and encourage self-management treatment goals is suggested when appropriate. Examples of needed communication for alternative behaviors include a specific regimen relating to physical activity; a specific sodium-reduced meal plan indi- cating selections for breakfast, lunch, and dinner; lifestyle recommendations relating to sleep, rest, and relaxation; and finally, suggestions and alternatives to environmental barri- ers, such as barriers that prevent healthy food shopping or limit reliable transportation to and from appointments with health providers and pharmacy visits. 13.2. Access to Health Insurance and Medication Assistance Plans Health insurance and medication plan assistance for patients is especially important to improving access to and affordability of medical care and BP medications. Learning how the patient financially supports and budgets for his or her medical care and medications offers the opportunity to share additional insight relating to cost reductions, including restructured payment plans. Ideally, this would improve the patient s compliance with medication adherence and treatment goals. 13.3. Social and Community Services Health care can be strengthened through local partner- ships. Hypertensive patients, particularly patients with lower incomes, have more opportunity to achieve treatment goals with the assistance of strong local partnerships. In patients with low socioeconomic status or patients who are challenged by social situations, integration of social and community services offers complementary reinforcement of clinically identified treatment goals. Social and community services are helpful when explicitly related to medical care. However, additional Table 22.


Social and community services are helpful when explicitly related to medical care. However, additional Table 22. Evidence-Based Elements of the Plan of Care for Patients With Hypertension Plan of Care Associated Section(s) of Guideline and Other Reference(s) Pharmacological and nonpharmacological treatments Medication selection (initial and ongoing) Monitoring for adverse effects and adherence Nonpharmacological interventions Diet Exercise Weight loss if overweight Moderate alcohol consumption Management of common comorbidities and conditions Ischemic heart disease Section 9.1S13.1-3,S13.1-4 Heart failure Reduced ejection fraction Preserved ejection fraction Diabetes mellitus Section 9.6S13.1-6 Chronic kidney disease Section 9.3 Cerebrovascular disease Section 9.4 Peripheral artery disease Section 9.5 Atrial fibrillation Section 9.8 Valvular heart disease Section 9.9 Left ventricular hypertrophy Section 7.3 Thoracic aortic disease Section 9.10 Patient and family education Achieving BP control and self-monitoring Sections 4.2, 8.2 Risk assessment and prognosis Section 8.1.2 Sexual activity and dysfunction Section 11.4 Special patient groups Pregnancy Section 10.2.2 Older persons Section 10.3.1 Children and adolescents Section 10.3.2 Metabolic syndrome Section 9.7 Possible secondary causes of hypertension Resistant hypertension Section 11.1 Patients with hypertension undergoing surgery Renal transplantation Section 9.3.1 Psychosocial factors Sex-specific issues Section 10.2 Culturally sensitive issues (race and ethnicity) Resource constraints Section 12.5 (Continued) Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e77 financial support and financial services are incredibly benefi- cial to patients, some of whom may choose to skip a doctor s appointment to pay a residential utility bill. 14. Summary of BP Thresholds and Goals for Pharmacological Therapy Several different BP thresholds and goals for the long-term treatment of hypertension with pharmacological therapy are recommended in this guideline. To provide a quick reference for practicing clinicians, these are summarized for hyperten- sive patients in general and for those with specific comorbidi- ties in Table 23. 15.


To provide a quick reference for practicing clinicians, these are summarized for hyperten- sive patients in general and for those with specific comorbidi- ties in Table 23. 15. Evidence Gaps and Future Directions In the present guideline, the writing committee was able to call on the large body of literature on BP and hypertension to make strong recommendations across a broad range of medical con- ditions. Nonetheless, significant gaps in knowledge exist. Importantly, there are areas where epidemiological and natural history studies suggest that hypertension prevention or earlier treatment of hypertension might substantially improve outcomes, but clinical trials are lacking to provide guidance. The combination of epidemiological data showing a graded relationship between BP and outcomes, particularly above a BP of 120/80 mm Hg, and the results of the SPRINT trial showing benefit of more comprehensive treatment to a target BP of <120/80 mm Hg, suggests that a lifelong BP below that level will substantially lower CVD and CKD incidence. This is especially the case for younger individuals, those with DM, and those with high lifetime CVD risk based on the presence of multiple risk factors, including high BP. If hard, cardiovascular outcome clinical trials remain the sole driver of evidence-based guidelines, then determining the full benefit of earlier interven- tion may not be possible because of the cost and length of time needed for intervention. Outcomes may be different if antihy- pertensive treatment is initiated earlier in the natural history of CVD. DM may provide a population in whom to test this hypothesis. Composite outcomes that include both prevention of events and surrogates, such as prevention of decline in renal function or amelioration of measures of subclinical atheroscle- rosis, vascular stiffness, or LV structure and function, should be considered.


Composite outcomes that include both prevention of events and surrogates, such as prevention of decline in renal function or amelioration of measures of subclinical atheroscle- rosis, vascular stiffness, or LV structure and function, should be considered. Otherwise, these younger individuals may be undertreated and experience mortality or CVD events before being old enough to enter hard outcome driven trials such as SPRINT. Replication of SPRINT, especially in younger patients with DM and in countries where nonischemic stroke is the predominant cause of CVD, is highly desirable. Likewise, implementation studies that demonstrate the practicality of SPRINT-like interventions in resource-constrained practice settings are needed. More information is urgently needed relating hypertensive target organ damage to CVD risk and outcomes. Should the identification of target organ damage and hypertensive heart disease prompt more aggressive BP management (ie, increase the rationale for instituting pharmacological therapy earlier or more intensively? Should all patients with hypertension be screened with echocardiogram for LVH? Should echocardiog- raphy be repeated once LVH is noted? Is it important to docu- ment LVH regression? At present, there are no RCT data to inform guideline recommendations. ABPM and HBPM provide enhanced ability to both diag- nose hypertension and monitor treatment. Although evidence is sufficient to recommend incorporating these tools into clini- cal practice, more knowledge about them is required. Areas of inquiry include closer mapping of the relationship of out- comes to ambulatory and home BP measurements, so that definitions of hypertension and hypertension severity based on Clinician follow-up, monitoring, and care coordination Follow-up visits Sections 8.1.3, Team-based care Section 12.2 Electronic health record Section 12.3.1 Health information technology tools for remote and self-monitoring Socioeconomic and cultural factors Health literacy Section 13.1.3 Access to health insurance and medication assistance plans Social services Section 13.1.3 Community services Section 13.1.3 BP indicates blood pressure.


Areas of inquiry include closer mapping of the relationship of out- comes to ambulatory and home BP measurements, so that definitions of hypertension and hypertension severity based on Clinician follow-up, monitoring, and care coordination Follow-up visits Sections 8.1.3, Team-based care Section 12.2 Electronic health record Section 12.3.1 Health information technology tools for remote and self-monitoring Socioeconomic and cultural factors Health literacy Section 13.1.3 Access to health insurance and medication assistance plans Social services Section 13.1.3 Community services Section 13.1.3 BP indicates blood pressure. Table 22. Continued Plan of Care Associated Section(s) of Guideline and Other Reference(s) Table 23. BP Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Conditions Clinical Condition(s) BP Threshold, mm Hg BP Goal, mm Hg General Clinical CVD or 10-year ASCVD No clinical CVD and 10-year ASCVD risk <10% Older persons ( 65 years of age; noninstitutionalized, ambulatory, community-living adults) Specific comorbidities Chronic kidney disease 130/80 <130/80 Chronic kidney disease after renal transplantation Stable ischemic heart disease 130/80 <130/80 Secondary stroke prevention 140/90 <130/80 Peripheral artery disease 130/80 <130/80 ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CVD, cardiovascular disease; and SBP, systolic blood pressure. these measures can be developed, including the importance of masked hypertension, white coat hypertension, and nocturnal hypertension. Reproducibility of ambulatory and home BPs must be studied, and cohorts should include a broader range of ethnicities. Trials with entry criteria and treatment goals based on ambulatory or home BP measures should be con- ducted, including studies of masked and white coat hyperten- sion. The practicality and cost of incorporating ABPM into EHR and routine care should be assessed. The existence of these techniques should not hamper efforts to investigate ways to improve accuracy in the measurement of clinic BP.


The existence of these techniques should not hamper efforts to investigate ways to improve accuracy in the measurement of clinic BP. Further research on improving accuracy of office BP measurements, including number of measurements, training of personnel mea- suring BP, and device comparisons, will help standardize care and thus improve outcomes. Technology for measurement of BP continues to evolve with the emergence of cuffless devices and other strategies that provide the opportunity for continuous noninvasive assessment of BP. The accuracy, cost, and useful- ness of these new technologies will need to be assessed. The contemporary healthcare environment is dramatically different from the era in which awareness of hypertension as a risk factor and benefits of treatment were discovered. With the advent of the EHR, complex calculations of CVD risk and renal function can be incorporated into routine reports, and many new avenues to support intervention strategies are avail- able to clinicians. Optimizing these approaches will require continued focused research. Recognition that simply applying what we know about BP control would have a large impact on population health, observations on inefficiencies and excessive cost in the US healthcare system, and the growth of information technology have led to promising studies of ways to improve and monitor hypertension care. Results of this research are reflected in this guideline, but further work is required. Examples for study include the effectiveness of mul- tidisciplinary healthcare teams to achieve BP treatment goals at lower cost, social media to maintain contact with patients, information technology to monitor outcomes and decrease practice variability, and incentives to providers to achieve bet- ter outcomes for patients. A key goal of these efforts should be to demonstrate reduction in healthcare disparities across ethnicity, sex, social and economic class, and age barriers.


A key goal of these efforts should be to demonstrate reduction in healthcare disparities across ethnicity, sex, social and economic class, and age barriers. More research on the prevention of the development of hypertension and the benefit of lifetime low BP should be conducted. In this regard, elucidation of genetic expression, epigenetic effects, transcriptomics, and proteomics that link genotypes with longitudinal databases may add consider- able knowledge about beneficial outcomes of lifelong lower BP, determinants of rise in BP over time, and identification of new treatment targets through understanding the under- lying pathophysiological mechanisms. Research should be directed toward the development of therapies that directly counteract the mechanisms accounting for the development of hypertension and disease progression. Additional research aimed at development of practical approaches to implemen- tation of clinical and population-based strategies to prevent obesity, increase physical fitness, and control excess salt and sugar intake could have significant public health impact. In addition, there are minimal, if any, data on whether treatment of hypertension during pregnancy mitigates risk; thus, there is a need for further research in this area, considering both proximate (during the pregnancy and postpartum period) and distant (CVD prevention) outcomes.S15-1 In the very old, frailty and higher risk of medication side effects complicate treatment. Additional knowledge of the effects of antihypertensive treatment for patients with demen- tia and patients who reside in long-term-care facility settings is needed. The best approach to older persons who have supine hypertension but postural hypotension needs to be clarified. Further research related to shared decision-making with patients and their families is needed.


Further research related to shared decision-making with patients and their families is needed. Examples include areas where evidence does not clearly identify one treatment or goal as substantially better than another, where improved patient knowledge (or improved provider knowledge of the patient s circumstances) might improve compliance, where reliance on patient collaboration improves achievement of outcomes (eg, HBPM, use of social media), and where there are competing health concerns (eg, older individuals with frailty). Finally, clinical guidelines are increasingly required to man- age the large body of accumulated knowledge related to diag- nosis and management of high BP. However, guidelines often cause controversy and confusion when competing recommen- dations are made by different expert groups or when changes in definitions, treatments, or treatment goals are introduced. Now may be the time to begin the investigation of the impact of guidelines on clinical practice, costs, and patient outcomes, as well as ways to facilitate communication and collaboration between different guideline-developing organizations. This document is, as its name implies, a guide. In managing patients, the responsible clinician s judgment remains paramount.


In managing patients, the responsible clinician s judgment remains paramount. Presidents and Staff American College of Cardiology Mary Norine Walsh, MD, MACC, President Shalom Jacobovitz, Chief Executive Officer William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and Publishing MaryAnne Elma, MPH, Senior Director, Science, Education, Quality, and Publishing Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing American College of Cardiology/American Heart Association Katherine A. Sheehan, PhD, Director, Guideline Strategy and Operations Abdul R. Abdullah, MD, Science and Medicine Advisor Naira Tahir, MPH, Associate Guideline Advisor American Heart Association John J. Warner, MD, President Nancy Brown, Chief Executive Officer Rose Marie Robertson, MD, FAHA, Chief Science and Medicine Officer Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations Jody Hundley, Manager, Production and Operations, Scientific Publications, Office of Science Operations Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e79 References Preamble P-1. Gibbons GH, Harold JG, Jessup M, et al. The next steps in devel- oping clinical practice guidelines for prevention. Circulation. 2013;128:1716 7. P-2. Gibbons GH, Shurin SB, Mensah GA, et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. Circulation. 2013;128: 1713 5. P-3. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (U.S.). Clinical Practice Guidelines We Can Trust. Washington, DC: The NationalAcademies Press; 2011. P-4. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (U.S.). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: The National Academies Press; 2011. P-5. Anderson JL, Heidenreich PA, Barnett PG, et al.


Washington, DC: The National Academies Press; 2011. P-5. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329 45. P-6. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association, 2010. Available at: http://assets.cardiosource.com/ Methodology_Manual_for_ACC_AHA_Writing_Committees. pdf and http://professional.heart.org/idc/groups/ahamah-public/@ September 15, 2017. P-7. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation clas- sification system: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426 28. P-8. Jacobs AK, Kushner FG, Ettinger SM. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:268 310. P-9. Jacobs AK, Anderson JL, Halperin JL. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:1208 17. P-10. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. Circulation. 2014;130:1662 67. S1.5-1. Society of Actuaries. Build and Blood Pressure Study, Vol 1. Ann Arbor, MI: The University of Michigan; 1959. S1.5-2. Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Cambridge, MA: Harvard University Press; 1980. S1.5-3. Effects of treatment on morbidity in hypertension. I.


Cambridge, MA: Harvard University Press; 1980. S1.5-3. Effects of treatment on morbidity in hypertension. I. Results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA. 1967;202:1028 34. S1.5-4. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA. 1970;213:1143 52. S1.5-5. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255 61. S1.5-6. Moser M, Roccella EJ. The treatment of hypertension: a remarkable success story. J Clin Hypertens (Greenwich). 2013;15:88 91. S1.5-7. Chobanian AV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. S1.5-8. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of theAmerican College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e116 e135. S1.5-9. Fihn SD, Gardin JM,Abrams J, et al. 2012ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354 471. S1.5-10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guide- line for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. S1.5-11. Gerhard-Herman MD, Gornik HL, Barrett C, et al.


2013;128:e240 327. S1.5-11. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ ACC guideline on the management of patients with lower extrem- ity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726 79. S1.5-12. Funder JW, Carey RM, Mantero F, et al. The management of pri- mary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889 1916. S1.5-13. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/ AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S1.5-14. Lenders JWM, Duh Q-Y, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guide- line. J Clin Endocrinol Metab. 2014;99:1915 42. S1.5-15. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guide- line for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199 267. S1.5-16. Nishimura RA, Otto CM, Bonow RO, et al. 2017AHA/ACC focused update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159 95. S1.5-17. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73.


2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S49 73. S1.5-18. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122 31. S1.5-19. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the man- agement of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137 61. S1.5-20. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S76 99. S1.5-21. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 219. S1.5-22. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(suppl 2):S102 38. S1.5-23. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarc- tion: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362 425. S1.5-24. Stone NJ, Robinson JG, Lichtenstein AH, et al.


2013;127:e362 425. S1.5-24. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atheroscle- rotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2):S1 45. S1.5-25. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147 97. S1.5-26. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guide- lines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. Circulation. 2011;123:1243 62. S1.5-27. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF second- ary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guide- line from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. Circulation. 2011;124:2458 73. S1.5-28. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guide- line for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584 636. S1.5-29. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/ AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic dis- ease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121:e266 369.


2010 ACCF/AHA/ AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic dis- ease: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121:e266 369. S1.5-30. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114: 555 76. S1.5-31. Elijovich F, Weinberger MH, Anderson CAM, et al. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68:e7 46. S1.5-32. Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health pol- icy statement on cardiovascular team-based care and the role of advanced practice providers. JAm Coll Cardiol. 2015;65:2118 36. S1.5-33. Rosendorff C, Lackland DT, Allison M, et al. Treatment of hyper- tension in patients with coronary artery disease: a scientific state- ment from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation. 2015;131:e435 70. S1.5-34. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014;63:1116 35. S1.5-35. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878 85. S1.5-36. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitor- ing. J Hypertens.


European Society of Hypertension position paper on ambulatory blood pressure monitor- ing. J Hypertens. 2013;31:1731 68. S1.5-37. Drozda J Jr, Messer JV, Spertus J, et al. ACCF/AHA/AMA- PCPI 2011 performance measures for adults with coronary artery disease and hypertension: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association- Physician Consortium for Performance Improvement. Circulation. 2011;124:248 70. S1.5-38. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for car- diovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122: 406 41. S1.5-39. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment:a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403 19. 2. BP and CVD Risk 2.1. Observational Relationship S2.1-1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. S2.1-2. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899 911. 2.2. BP Components S2.2-1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. S2.2-2. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899 911. S2.2-3. Rutan GH, Kuller LH, Neaton JD, et al.


2014;383:1899 911. S2.2-3. Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 1988;77:504 14. S2.2-4. Sesso HD, Stampfer MJ, Rosner B, et al. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in men. Hypertension. 2000;36:801 7. S2.2-5. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and dia- stolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598 615. S2.2-6. Benetos A, Thomas F, Bean K, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 2002;162:577 81. S2.2-7. Lindenstrom E, Boysen G, Nyboe J. Influence of systolic and dia- stolic blood pressure on stroke risk: a prospective observational study. Am J. Epidemiol. 1995;142:1279 90. S2.2-8. Zhao L, Song Y, Dong P, et al. Brachial pulse pressure and cardio- vascular or all-cause mortality in the general population: a meta- analysis of prospective observational studies. J Clin Hypertens (Greenwich). 2014;16:678 85. S2.2-9. Mosley WJ, Greenland P, Garside DB, et al. Predictive utility of pulse pressure and other blood pressure measures for cardiovascular outcomes. Hypertension. 2007;49:1256 64. S2.2-10. Franklin SS, Lopez VA, Wong ND, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009;119:243 50. S2.2-11. Kodama S, Horikawa C, Fujihara K, et al. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pres- sure and cardiovascular risk in patients with diabetes mellitus. Am J Cardiol. 2014;113:1058 65. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e81 2.3. Population Risk S2.3-1. Lim SS, Vos T, Flaxman AD, et al.


Population Risk S2.3-1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assess- ment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224 60. S2.3-2. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hyper- tension and systolic blood pressure of at Least 110 to 115 mmHg, 1990 2015. JAMA. 2017;317:165 82. S2.3-3. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009;6:e1000058. S2.3-4. Ford ES. Trends in mortality from all causes and cardiovascular dis- ease among hypertensive and nonhypertensive adults in the United States. Circulation. 2011;123:1737 44. S2.3-5. Cheng S, Claggett B, CorreiaAW, et al. Temporal trends in the popu- lation attributable risk for cardiovascular disease: theAtherosclerosis Risk in Communities Study. Circulation. 2014;130:820 8. S2.3-6. Willey JZ, Moon YP, Kahn E, et al. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the northern Manhattan study. J Am Heart Assoc. 2014;3:e001106. S2.3-7. Saran R, Li Y, Robinson B, et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2015;66 Svii:S1 305. 2.4. Coexistence of Hypertension and Related Chronic Conditions S2.4-1. Wilson PW, Kannel WB, Silbershatz H, et al. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999;159:1104 9. S2.4-2. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular dis- ease. N Engl J Med. 2012;366:321 9. S2.4-3. Egan BM, Li J, Hutchison FN, et al. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals.


Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130:1692 9. S2.4-4. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: U.S. Department of Health and Human Services; 2014. S2.4-5. Muntner P, Anderson A, Charleston J, et al. Hypertension aware- ness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010;55:441 51. S2.4-6. Tanner RM, Calhoun DA, Bell EK, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8:1583 90. S2.4-7. Saydah S, Bullard KM, Cheng Y, et al. Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999 2010. Obesity (Silver Spring). 2014;22:1888 95. S2.4-8. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76:4 12. S2.4-9. Sarzani R, Salvi F, Dessi-Fulgheri P, et al. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hyperten- sion: an integrated view in humans. J Hypertens. 2008;26:831 43. S2.4-10. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560 3. S2.4-11. Kim J, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecu- lar and pathophysiological mechanisms. Circulation. 2006;113: 1888 904. S2.4-12. McEvoy RD, Antic NA, Heeley E, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375:919 31. 3. Classification of BP 3.1. Definition of High BP S3.1-1. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. S3.1-2.


Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of indi- vidual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903 13. S3.1-2. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1 25 million people. Lancet. 2014;383:1899 911. S3.1-3. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957 67. S3.1-4. Guo X, Zhang X, Guo L, et al. Association between pre-hyperten- sion and cardiovascular outcomes: a systematic review and meta- analysis of prospective studies. Curr Hypertens Rep. 2013;15: 703 16. S3.1-5. Guo X, Zhang X, Zheng L, et al. Prehypertension is not associated with all-cause mortality: a systematic review and meta-analysis of prospective studies. PLoS ONE. 2013;8:e61796. S3.1-6. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a meta-analysis. Neurology. 2014;82:1153 61. S3.1-7. HuangY, Cai X, Liu C, et al. Prehypertension and the risk of coro- nary heart disease in Asian and Western populations: a meta-analysis. J Am Heart Assoc. 2015;4:e001519. S3.1-8. Huang Y, Cai X, Zhang J, et al. Prehypertension and incidence of ESRD: a systematic review and meta-analysis. Am J Kidney Dis. 2014;63:76 83. S3.1-9. Huang Y, Su L, Cai X, et al. Association of all-cause and cardiovas- cular mortality with prehypertension: a meta-analysis. Am Heart J. 2014;167:160 8.e1. S3.1-10. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Med. 2013; 11:177. S3.1-11. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. S3.1-12.


Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. S3.1-12. Lee M, Saver JL, Chang B, et al. Presence of baseline prehyper- tension and risk of incident stroke: a meta-analysis. Neurology. 2011;77:1330 7. S3.1-13. Shen L, Ma H, Xiang M-X, et al. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol. 2013;112:266 71. S3.1-14. Sundstrom J, Arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analy- sis. Ann Intern Med. 2015;162:184 91. S3.1-15. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at differ- ent baseline and achieved blood pressure levels overview and meta- analyses of randomized trials. J Hypertens. 2014;32:2296 304. S3.1-16. Wang S, Wu H, Zhang Q, et al. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general popu- lation: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168:4857 60. S3.1-17. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435 43. S3.1-18. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393 404. S3.1-19. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbid- ity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995 1003. S3.1-20. Wald DS, Law M, Morris JK, et al.


2002;359:995 1003. S3.1-20. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med. 2009;122:290 300. S3.1-21. ChobanianAV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. S3.1-22. Yoon SS, Gu Q, Nwankwo T, et al. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension. 2015;65:54 61. 3.2. Lifetime Risk of Hypertension S3.2-1. Muntner P, Woodward M, Mann DM, et al. Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis. Hypertension. 2010;55:1339 45. S3.2-2. Parikh NI, Pencina MJ, Wang TJ, et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med. 2008;148:102 10. S3.2-3. Carson AP, Howard G, Burke GL, et al. Ethnic differences in hyper- tension incidence among middle-aged and older adults: the multi- ethnic study of atherosclerosis. Hypertension. 2011;57:1101 07. S3.2-4. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003 10. S3.2-5. Shihab HM, Meoni LA, Chu AY, et al. Body mass index and risk of incident hypertension over the life course: the Johns Hopkins Precursors Study. Circulation. 2012;126:2983 9. 3.3. Prevalence of High BP S3.3-1. Whelton PK. The elusiveness of population-wide high blood pres- sure control. Annu Rev Public Health. 2015;36:109 30. S3.3-2. Crim MT, Yoon SSS, Ortiz E, et al. National surveillance defini- tions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes. 2012;5:343 51. S3.3-3.


National surveillance defini- tions for hypertension prevalence and control among adults. Circ Cardiovasc Qual Outcomes. 2012;5:343 51. S3.3-3. ChobanianAV, Bakris GL, Black HR, et al; the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206 52. S3.3-4. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study. JAMA. 1977;237:255 61. S3.3-5. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154 83. S3.3-6. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988 1991. Hypertension. 1995;25:305 13. S3.3-7. Gee ME, Campbell N, Sarrafzadegan N, et al. Standards for the uniform reporting of hypertension in adults using population survey data: recommendations from the World Hypertension League Expert Committee. J Clin Hypertens (Greenwich). 2014;16:773 81. 3.4. Awareness, Treatment, and Control S3.4-1. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension. 1995;26:60 9. S3.4-2. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988 2000. JAMA. 2003;290:199 206. S3.4-3. Egan BM, Li J, Hutchison FN, et al. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130:1692 9. S3.4-4. Nwankwo T, Yoon SS, Burt V, et al. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011 2012. NCHS Data Brief. 2013:1 8. S3.4-5. National Center for Health Statistics (U.S.).


NCHS Data Brief. 2013:1 8. S3.4-5. National Center for Health Statistics (U.S.). Health, United States, 2013: With Special Feature on Prescription Drugs. Hyattsville, MD: National Center for Health Statistics (U.S.); 2014. S3.4-6. Bromfield SG, Bowling CB, Tanner RM, et al. Trends in hyperten- sion prevalence, awareness, treatment, and control among US adults 80 years and older, 1988 2010. J Clin Hypertens (Greenwich). 2014;16:270 6. S3.4-7. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575 85. S3.4-8. TheALLHAT Officers and Coordinators for theALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients ran- domized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981 97. S3.4-9. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease out- comes in adults aged 75 years: a randomized clinical trial. JAMA. 2016;315:2673 82. S3.4-10. Fletcher RD, Amdur RL, Kolodner R, et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation. 2012;125:2462 8. S3.4-11. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699 705. S3.4-12. Jaffe MG, Young JD. The Kaiser Permanente Northern California story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens (Greenwich). 2016;18:260 1. 4. Measurement of BP 4.1. Accurate Measurement of BP in the Office S4.1-1. Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, pre- vention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557 76. S4.1-2. Pickering TG, Hall JE, Appel LJ, et al.


2017;33:557 76. S4.1-2. Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for profession- als from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111:697 716. S4.1-3. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guide- lines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 219. S4.1-4. Weir MR. In the clinic: hypertension. Ann Intern Med. 2014;161: ITC1 15. S4.1-5. Liu C, Griffiths C, Murray A, et al. Comparison of stethoscope bell and diaphragm, and of stethoscope tube length, for clinical blood pressure measurement. Blood Press Monit. 2016;21:178 83. S4.1-6. Kantola I, Vesalainen R, Kangassalo K, et al. Bell or dia- phragm in the measurement of blood pressure? J Hypertens. 2005;23:499 503. 4.2. Out-of-Office and Self-Monitoring of BP S4.2-1. Uhlig K, Balk EM, Patel K, et al. Self-Measured Blood Pressure Monitoring: Comparative Effectiveness. Rockville, MD: Agency for Healthcare Research and Quality (U.S.); 2012. S4.2-2. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46 56. S4.2-3. McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hyperten- sive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312:799 808. S4.2-4. Siu AL. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163:778 86. S4.2-5. Yi SS, Tabaei BP, Angell SY, et al.


2015;163:778 86. S4.2-5. Yi SS, Tabaei BP, Angell SY, et al. Self-blood pressure monitor- ing in an urban, ethnically diverse population: a randomized clini- cal trial utilizing the electronic health record. Circ Cardiovasc Qual Outcomes. 2015;8:138 45. S4.2-6. Agarwal R, Bills JE, Hecht TJW, et al. Role of home blood pres- sure monitoring in overcoming therapeutic inertia and improv- ing hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29 38. S4.2-7. O'Brien E, Stergiou GS. The pursuit of accurate blood pressure measurement: a 35-year travail. J Clin Hypertens (Greenwich). 2017;19:746 52. S4.2-8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159 219. S4.2-9. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: a joint sci- entific statement from the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008;52:10 29. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e83 S4.2-10. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011. 4.3. Ambulatory BP Monitoring S4.3-1. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure mon- itoring. N Engl J Med. 2006;354:2368 74. S4.3-2. Tunis SR. Decision Memo for Ambulatory Blood Pressure Monitoring (CAG-00067N). Centers for Medicare and Medicaid Services; October 17, 2001. S4.3-3. Shimbo D, Kent ST, Diaz KM, et al. The use of ambulatory blood pressure monitoring among Medicare beneficiaries in 2007 2010. J Am Soc Hypertens. 2014;8:891 7. S4.3-4. Kent ST, Shimbo D, Huang L, et al.


2014;8:891 7. S4.3-4. Kent ST, Shimbo D, Huang L, et al. Rates, amounts, and deter- minants of ambulatory blood pressure monitoring claim reim- bursements among Medicare beneficiaries. J Am Soc Hypertens. 2014;8:898 908. S4.3-5. Dabl Educational Trust. Information on validated blood pressure devices and monitors. Available at: http://www.dableducational.org. Accessed September 17, 2017. S4.3-6. British Hypertension Society. BP Monitors. Available at: http:// www.bhsoc.org/bp-monitors/bp-monitors. Accessed September 17, 2017. S4.3-7. Pickering TG, White WB; American Society of Hypertension Writing Group. ASH position paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambu- latory blood pressure monitoring. J Clin Hypertens (Greenwich). 2008;10:850 5. S4.3-8. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure moni- toring. J Hypertens. 2013;31:1731 68. S4.3-9. Kikuya M, Hansen TW, Thijs L, et al. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovas- cular risk. Circulation. 2007;115:2145 52. S4.3-10. Niiranen TJ, Asayama K, Thijs L, et al. Outcome-driven thresh- olds for home blood pressure measurement: international database of home blood pressure in relation to cardiovascular outcome. Hypertension. 2013;61:27 34. S4.3-11. Head GA, Mihailidou AS, Duggan KA, et al. Definition of ambula- tory blood pressure targets for diagnosis and treatment of hyperten- sion in relation to clinic blood pressure: prospective cohort study. BMJ. 2010;340:c1104. S4.3-12. Hansen TW, Kikuya M, Thijs L, et al. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. J Clin Hypertens (Greenwich). 2008;10:377 81. S4.3-13. Ravenell J, Shimbo D, Booth JN 3rd, et al. Thresholds for ambula- tory blood pressure among African Americans in the Jackson Heart Study. Circulation. 2017;135:2470 80. S4.3-14. Hansen TW, Kikuya M, Thijs L, et al.


2017;135:2470 80. S4.3-14. Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7 030 individuals. J Hypertens. 2007;25:1554 64. S4.3-15. Roush GC, Fagard RH, Salles GF, et al. Prognostic impact from clinic, daytime, and night-time systolic blood pressure in nine cohorts of 13 844 patients with hypertension. J Hypertens. 2014;32:2332 40. S4.3-16. Mancia G, Bombelli M, Facchetti R, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension. 2009;54:226 32. S4.3-17. Ben-Dov IZ, Ben-Arie L, Mekler J, et al. Reproducibility of white- coat and masked hypertension in ambulatory BP monitoring. Int J Cardiol. 2007;117:355 9. S4.3-18. Bidlingmeyer I, Burnier M, Bidlingmeyer M, et al. Isolated office hypertension:aprehypertensivestate?JHypertens.1996;14:327 32. S4.3-19. Muxfeldt ES, Fiszman R, de Souza F, et al. Appropriate time inter- val to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension. 2012;59: 384 9. S4.3-20. Palatini P, Winnicki M, Santonastaso M, et al. Prevalence and clinical significance of isolated ambulatory hypertension in young subjects screened for stage 1 hypertension. Hypertension. 2004;44:170 4. S4.3-21. Trudel X, Milot A, Brisson C. Persistence and progression of masked hypertension: a 5-year prospective study. Int J Hypertens. 2013;2013:836387. S4.3-22. Ugajin T, Hozawa A, Ohkubo T, et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med. 2005;165:1541 6. 4.4. Masked and White Coat Hypertension S4.4-1. Pickering TG, James GD, Boddie C, et al. How common is white coat hypertension? JAMA. 1988;259:225 8. S4.4-2. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162:192 204. S4.4-3.


Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162:192 204. S4.4-3. Ohkubo T, Kikuya M, Metoki H, et al. Prognosis of masked hypertension and white-coat hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. J Am Coll Cardiol. 2005;46:508 15. S4.4-4. Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normo- tension: a meta-analysis. J Hypertens. 2007;25:2193 8. S4.4-5. National Clinical Guideline Centre (UK). Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34. London, UK: Royal College of Physicians (UK); 2011. S4.4-6. Asayama K, Thijs L, Li Y, et al. Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the popula- tion. Hypertension. 2014;64:935 42. S4.4-7. Mancia G, Bombelli M, Brambilla G, et al. Long-term prognos- tic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements. Hypertension. 2013;62:168 74. S4.4-8. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in ini- tially untreated subjects: an updated meta analysis. Am J Hypertens. 2011;24:52 8. S4.4-9. Viera AJ, Hinderliter AL, Kshirsagar AV, et al. Reproducibility of masked hypertension in adults with untreated borderline office blood pressure: comparison of ambulatory and home monitoring. Am J Hypertens. 2010;23:1190 7. S4.4-10. Viera AJ, Lin F-C, Tuttle LA, et al. Reproducibility of masked hypertension among adults 30 years or older. Blood Press Monit. 2014;19:208 15. S4.4-11. Stergiou GS, Asayama K, Thijs L, et al. Prognosis of white-coat and masked hypertension: International Database of Home Blood Pressure in Relation to Cardiovascular Outcome. Hypertension.


Prognosis of white-coat and masked hypertension: International Database of Home Blood Pressure in Relation to Cardiovascular Outcome. Hypertension. 2014;63:675 82. S4.4-12. Tomiyama M, Horio T, Yoshii M, et al. Masked hypertension and target organ damage in treated hypertensive patients. Am J Hypertens. 2006;19:880 6. S4.4-13. Perloff D, Sokolow M, Cowan R. The prognostic value of ambula- tory blood pressures. JAMA. 1983;249:2792 8. S4.4-14. Pickering TG, Davidson K, Gerin W, et al. Masked hypertension. Hypertension. 2002;40:795 6. S4.4-15. Banegas JR, Ruilope LM, de la Sierra A, et al. High prevalence of masked uncontrolled hypertension in people with treated hyperten- sion. Eur Heart J. 2014;35:3304 12. S4.4-16. Gorostidi M, Vinyoles E, Banegas JR, et al. Prevalence of white- coat and masked hypertension in national and international regis- tries. Hypertens Res. 2015;38:1 7. S4.4-17. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diag- nosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403 19. S4.4-18. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure moni- toring. J Hypertens. 2013;31:1731 68. S4.4-19. WangYC, Shimbo D, Muntner P, et al. Prevalence of masked hyper- tension among US Adults with nonelevated clinic blood pressure. Am J Epidemiol. 2017;185:194 202. S4.4-20. Peacock J, Diaz KM, Viera AJ, et al. Unmasking masked hyper- tension: prevalence, clinical implications, diagnosis, correlates and future directions. J Hum Hypertens. 2014;28:521 8. S4.4-21. Conen D, Aeschbacher S, Thijs L, et al. Age-specific differences between conventional and ambulatory daytime blood pressure val- ues. Hypertension. 2014;64:1073 9. S4.4-22. Alwan H, Pruijm M, Ponte B, et al. Epidemiology of masked and white-coat hypertension: the family-based SKIPOGH study. PLoS ONE. 2014;9:e92522. S4.4-23. Shimbo D, Newman JD, Schwartz JE.


PLoS ONE. 2014;9:e92522. S4.4-23. Shimbo D, Newman JD, Schwartz JE. Masked hypertension and prehypertension: diagnostic overlap and interrelationships with left ventricular mass: the Masked Hypertension Study. Am J Hypertens. 2012;25:664 71. S4.4-24. Franklin SS, Thijs L, Asayama K, et al. The cardiovascular risk of white coat hypertension. J Am Coll Cardiol. 2016;68:2033 43. S4.4-25. Tientcheu D, Ayers C, Das SR, et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol. 2015;66:2159 69. S4.4-26. Briasoulis A, Androulakis E, Palla M, et al. White-coat hyperten- sion and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593 9. S4.4-27. Siu AL; U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015;163: 778 86. S4.4-28. Bayo J, Cos FX, Roca C, et al. Home blood pressure self-moni- toring: diagnostic performance in white-coat hypertension. Blood Press Monit. 2006;11:47 52. S4.4-29. Nasothimiou EG, Tzamouranis D, Rarra V, et al. Diagnostic accu- racy of home vs. ambulatory blood pressure monitoring in untreated and treated hypertension. Hypertens Res. 2012;35:750 5. S4.4-30. Sega R, Trocino G, Lanzarotti A, et al. Alterations of cardiac struc- ture in patients with isolated office, ambulatory, or home hyper- tension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001;104:1385 92. S4.4-31. Hansen TW, Kikuya M, Thijs L, et al. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7 030 individuals. J Hypertens. 2007;25:1554 64. S4.4-32. Diaz KM, Veerabhadrappa P, Brown MD, et al. Prevalence, determi- nants, and clinical significance of masked hypertension in a popula- tion-based sample of African Americans: the Jackson Heart Study. Am J Hypertens. 2015;28:900 8. S4.4-33.


Prevalence, determi- nants, and clinical significance of masked hypertension in a popula- tion-based sample of African Americans: the Jackson Heart Study. Am J Hypertens. 2015;28:900 8. S4.4-33. Andalib A, Akhtari S, Rigal R, et al. Determinants of masked hyper- tension in hypertensive patients treated in a primary care setting. Intern Med J. 2012;42:260 6. S4.4-34. Terawaki H, Metoki H, Nakayama M, et al. Masked hypertension determined by self-measured blood pressure at home and chronic kidney disease in the Japanese general population: the Ohasama study. Hypertens Res. 2008;31:2129 35. 5. Causes of Hypertension 5.1. Genetic Predisposition S5.1-1. Kaplan NM. Primary hypertension: pathogenesis. In: Kaplan's Clinical Hypertension. Philadelphia, PA: Lippincott Williams & Wilkins; 200650 121. S5.1-2. Padmanabhan S, Caulfield M, DominiczakAF. Genetic and molecu- lar aspects of hypertension. Circ Res. 2015;116:937 59. S5.1-3. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104:545 56. S5.1-4. Dominiczak AF, Kuo D. Hypertension: update 2017. Hypertension. 2017;69:3 4. S5.1-5. Ference BA, Julius S, Mahajan N, et al. Clinical effect of natu- rally random allocation to lower systolic blood pressure beginning before the development of hypertension. Hypertension. 2014;63: 1182 8. 5.2. Environmental Risk Factors S5.2-1. Savica V, Bellinghieri G, Kopple JD. The effect of nutrition on blood pressure. Annu Rev Nutr. 2010;30:365 401. S5.2-2. Chan Q, Stamler J, Griep LMO, et al. An update on nutrients and blood pressure. J Atheroscler Thromb. 2016;23:276 89. S5.2-3. Tang WHW, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120:1183 96. 5.2.1. Overweight and Obesity S5.2.1-1. Bray GA. Life insurance and overweight. Obes Res. 1995;3:97 9. S5.2.1-2. Harsha DW, Bray GA. Weight loss and blood pressure control (Pro). Hypertension. 2008;51:1420 5; discussion 1425. S5.2.1-3. Hubert HB, Feinleib M, McNamara PM, et al.


2008;51:1420 5; discussion 1425. S5.2.1-3. Hubert HB, Feinleib M, McNamara PM, et al. Obesity as an indepen- dent risk factor for cardiovascular disease: a 26-year follow-up of partici- pants in the Framingham Heart Study. Circulation. 1983;67:968 77. S5.2.1-4. Huang Z, Willett WC, Manson JE, et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med. 1998;128:81 8. S5.2.1-5. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41:625 33. S5.2.1-6. Jones DW, Kim JS, Andrew ME, et al. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens. 1994;12:1433 7. S5.2.1-7. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8:270 8. S5.2.1-8. Garrison RJ, Kannel WB, Stokes J 3rd, et al. Incidence and precur- sors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16:235 51. S5.2.1-9. Forman JP, Stampfer MJ, Curhan GC. Diet and lifestyle risk fac- tors associated with incident hypertension in women. JAMA. 2009;302:401 11. Juonala M, Magnussen CG, Berenson GS, et al. Childhood adipos- ity, adult adiposity, and cardiovascular risk factors. N Engl J Med. 2011;365:1876 85. 5.2.2. Sodium Intake S5.2.2-11. Klag MJ, He J, Coresh J, et al. The contribution of urinary cations to the blood pressure differences associated with migration. Am J Epidemiol. 1995;142:295 303. S5.2.2-12. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excre- tion. Intersalt Cooperative Research Group. BMJ. 1988;297:319 28. S5.2.2-13. Mente A, O'Donnell MJ, Rangarajan S, et al. Association of uri- nary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371:601 11. S5.2.2-14. Elliott P, Stamler J, Nichols R, et al.


2014;371:601 11. S5.2.2-14. Elliott P, Stamler J, Nichols R, et al. Intersalt revisited: further anal- yses of 24 hour sodium excretion and blood pressure within and across populations. Intersalt Cooperative Research Group. BMJ. 1996;312:1249 53. S5.2.2-15. Takase H, Sugiura T, Kimura G, et al. Dietary sodium consump- tion predicts future blood pressure and incident hypertension in the Japanese normotensive general population. J Am Heart Assoc. 2015;4:e001959. S5.2.2-16. Stamler J. The INTERSALT study: background, methods, findings, and implications. Am J Clin Nutr. 1997;65:626S 42S. S5.2.2-17. Strazzullo P, D'Elia L, Kandala NB, et al. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. BMJ. 2009;339:b4567. S5.2.2-18. Whelton PK. Sodium, potassium, blood pressure, and cardiovascu- lar disease in humans. Curr Hypertens Rep. 2014;16:465. S5.2.2-19. Whelton PK, Appel LJ, Sacco RL, et al. Sodium, blood pres- sure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012;126:2880 9. S5.2.2-20. Institute of Medicine. Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. 2005; The National Academies Press: Washington, DC. S5.2.2-21. Weinberger MH, Miller JZ, Luft FC, et al. Definitions and char- acteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986;8:II127 134. S5.2.2-22. Sanada H, Jones JE, Jose PA. Genetics of salt-sensitive hyperten- sion. Curr Hypertens Rep. 2011;13:55 66. S5.2.2-23. Carey RM, Schoeffel CD, Gildea JJ, et al. Salt sensitivity of blood pressure is associated with polymorphisms in the sodium-bicarbon- ate cotransporter. Hypertension. 2012;60:1359 66. S5.2.2-24. Elijovich F, Weinberger MH, Anderson CAM. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016;68:e7 46. S5.2.2-25. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481 90. S5.2.2-26. Cogswell ME, Zhang Z, Carriquiry AL, et al. Sodium and potas- sium intakes among US adults: NHANES 2003 2008. Am J Clin Nutr. 2012;96:647 57.


Sodium and potas- sium intakes among US adults: NHANES 2003 2008. Am J Clin Nutr. 2012;96:647 57. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e85 S5.2.2-27. Weinberger MH, Fineberg NS, Fineberg SE, et al. Salt sensitiv- ity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37:429 32. S5.2.2-28. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardio- vascular events in patients with essential hypertension. Lancet. 1997;350:1734 7. S5.2.2-29. Gu D, Zhao Q, Chen J, et al. Reproducibility of blood pressure responses to dietary sodium and potassium interventions: the GenSalt study. Hypertension. 2013;62:499 505. S5.2.3-30. Poulter N, Khaw KT, Hopwood BE, et al. Blood pressure and associated factors in a rural Kenyan community. Hypertension. 1984;6:810 3. S5.2.3-31. He J, Tell GS, TangYC, et al. Relation of electrolytes to blood pres- sure in men. The Yi people study. Hypertension. 1991;17:378 85. S5.2.3-32. Zhang Z, Cogswell ME, Gillespie C, et al. Association between usual sodium and potassium intake and blood pressure and hyper- tension among U.S. adults: NHANES 2005 2010. PLoS ONE. 2013;8:e75289. S5.2.3-33. Kieneker LM, Gansevoort RT, Mukamal KJ, et al. Urinary potas- sium excretion and risk of developing hypertension: the preven- tion of renal and vascular end-stage disease study. Hypertension. 2014;64:769 76. S5.2.3-34. D'Elia L, Barba G, Cappuccio FP, et al. Potassium intake, stroke, and cardiovascular disease a meta-analysis of prospective studies. J Am Coll Cardiol. 2011;57:1210 9. S5.2.3-35. D'Elia L, Iannotta C, Sabino P, et al. Potassium-rich diet and risk of stroke: updated meta-analysis. Nutr Metab Cardiovasc Dis. 2014;24:585 7. S5.2.3-36. Vinceti M, Filippini T, Crippa A, et al. Meta-analysis of potassium intake and the risk of stroke. J Am Heart Assoc. 2016;5:e004210. S5.2.3-37. Rodrigues SL, Baldo MP, Machado RC, et al.


2016;5:e004210. S5.2.3-37. Rodrigues SL, Baldo MP, Machado RC, et al. High potassium intake blunts the effect of elevated sodium intake on blood pressure levels. J Am Soc Hypertens. 2014;8:232 8. S5.2.3-38. Khaw KT, Barrett-Connor E. The association between blood pres- sure, age, and dietary sodium and potassium: a population study. Circulation. 1988;77:53 61. S5.2.3-39. Cook NR, Obarzanek E, Cutler JA, et al. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med. 2009;169:32 40. 5.2.4. Physical Fitness S5.2.4-40. Lesniak KT, Dubbert PM. Exercise and hypertension. Curr Opin Cardiol. 2001;16:356 9. S5.2.4-41. Hayashi T, Tsumura K, Suematsu C, et al. Walking to work and the risk for hypertension in men: the Osaka Health Survey. Ann Intern Med. 1999;131:21 6. S5.2.4-42. Leary AC, Donnan PT, MacDonald TM, et al. The influence of physical activity on the variability of ambulatory blood pressure. Am J Hypertens. 2000;13:1067 73. S5.2.4-43. Carnethon MR, Gidding SS, Nehgme R, et al. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. JAMA. 2003;290:3092 100. S5.2.4-44. Liu J, Sui X, Lavie CJ, et al. Effects of cardiorespiratory fitness on blood pressure trajectory with aging in a cohort of healthy men. J Am Coll Cardiol. 2014;64:1245 53. S5.2.5-45. Lian C. L'alcoholisme cause d'hypertension arterielle. Bull Acad Med (Paris). 1915;74:525 8. S5.2.5-46. Klatsky AL. Alcohol and cardiovascular mortality: common sense and scientific truth. J Am Coll Cardiol. 2010;55:1336 8. 5.3. Childhood Risk Factors and BP Tracking S5.3-1. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. 2008;117:3171 80. S5.3-2. Juhola J, Oikonen M, Magnussen CG, et al. Childhood physical, environmental, and genetic predictors of adult hypertension: the car- diovascular risk in young Finns study. Circulation. 2012;126:402 9.